These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21543293)

  • 21. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
    Studinger P; Tabák ÁG; Chen CH; Salvi P; Othmane TE; Torzsa P; Kapocsi J; Fekete BC; Tislér A
    J Clin Hypertens (Greenwich); 2013 Dec; 15(12):910-7. PubMed ID: 24119182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial.
    Punzi H; Lewin A; Lukić T; Goodin T; Wei Chen
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):349-57. PubMed ID: 21088095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude.
    Bilo G; Caldara G; Styczkiewicz K; Revera M; Lombardi C; Giglio A; Zambon A; Corrao G; Faini A; Valentini M; Mancia G; Parati G
    J Hypertens; 2011 Feb; 29(2):380-7. PubMed ID: 21045724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study.
    Patrianakos AP; Parthenakis FI; Mavrakis HE; Diakakis GF; Chlouverakis GI; Vardas PE
    Am Heart J; 2005 Nov; 150(5):985. PubMed ID: 16290981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A; Lasseter KC; Dong F; Whalen JC
    J Am Soc Hypertens; 2012; 6(3):228-36. PubMed ID: 22421631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension].
    Mustafaev II; Nurmamedova GS
    Kardiologiia; 2013; 53(2):48-54. PubMed ID: 23548391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of nebivolol in patients with mild and moderate hypertension].
    Zhigunova LV; Lakhova EL; Iurenev AP
    Ter Arkh; 2003; 75(3):59-61. PubMed ID: 12718224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ; Agrawal R; Lichtenthal A; Mäkel W; Fici F
    Am J Ther; 2006; 13(3):192-7. PubMed ID: 16772759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits.
    Szumny D; Szeląg A
    Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):917-23. PubMed ID: 24705852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
    Rosei EA; Rizzoni D; Comini S; Boari G;
    Blood Press Suppl; 2003 May; 1():30-5. PubMed ID: 12800985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ
    Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
    Vaïsse B; Ghobrial H; Vaur L; Poncelet P; Asmar R; Herpin D; Mallion JM
    Arch Mal Coeur Vaiss; 2001 Aug; 94(8):907-12. PubMed ID: 11575229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-four-hour blood pressure load as a surrogate end-point in assessing antihypertensive therapy.
    White WB; Lund-Johansen P; Omvik P
    J Hypertens Suppl; 1993 Jun; 11(4):S75-80. PubMed ID: 8377035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heart rate variability dynamics during treatment of arterial hypertension].
    Riabykina GV; Chazova IE; Mychka VB; Shutova LI; Shishova TV; Liutikova LN; Kozhemiakina ESh; Shchedrina EV; Sobolev AV
    Kardiologiia; 2008; 48(7):18-24. PubMed ID: 18789021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.